NEXGARD SPECTRA 75 MG 15 MG VETERINARY

Land: Israël

Taal: Engels

Bron: Ministry of Health

Koop het nu

Bijsluiter Bijsluiter (PIL)
24-10-2023
Productkenmerken Productkenmerken (SPC)
24-10-2023

Werkstoffen:

AFOXOLANER; MILBEMYCIN OXIME

Beschikbaar vanaf:

BEIT-EREZ HAVAT MILATIN LTD

farmaceutische vorm:

CHEWABLE TABLETS

Samenstelling:

AFOXOLANER 75 MG; MILBEMYCIN OXIME 15 MG

Toedieningsweg:

PER OS

Prescription-type:

Not required

Geproduceerd door:

BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

therapeutische indicaties:

For the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease (Dirofilaria immitis larvae), angiostrongylosis (reduction in level of immature adults (L5) and adults of Angiostrongylus vasorum) and/or treatment of gastrointestinal nematode infestations is indicated.Treatment of flea infestations (Ctenocephalides felis and C. canis) in dogs for 5 weeks.Treatment of tick infestations (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) in dogs for 4 weeks.Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum, Ancylostoma braziliense and Ancylostoma ceylanicum) and whipworm (Trichuris vulpis).Prevention of heartworm disease (Dirofilaria immitis larvae) with monthly administration.Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum) with monthly administration.Treatment of demodicosis (caused by Demodex canis).Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

Autorisatie datum:

2022-09-30

Bijsluiter

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Arabisch 24-10-2023
Bijsluiter Bijsluiter Hebreeuws 24-10-2023